CURE M.S.A. (Multiple System Atrophy)

CURE M.S.A. (Multiple System Atrophy) Multiple System Atrophy (MSA) is a rare, neurodegenerative disorder affecting multiple body systems. MSA can actually be considered three disorders in one.
1.

Major symptoms can occur in any combination including ataxia (loss of balance and coordination), severe low blood pressure leading to dizziness or fainting when standing, bladder retention or incontinence, constipation, male impotence, speech and swallowing difficulties, sleep disorders, breathing problems, and rigidity and tremor similar to Parkinson’s Disease. Sporadic Cerebellar Ataxia
2. Atypi

cal Parkinsonism (Parkinson’s Plus)
3. Autonomic Dysfunction (Dysautonomia)

In the past these terms were used to describe what were once thought to be three separate disorders:
1. Sporadic Olivopontocerebellar Atrophy (OPCA)
2. Striatonigral Degeneration (SND)
3. Shy-Drager Syndrome (SDS)

The currently recognized terminology includes only two types of MSA:
1. MSA-C when cerebellar symptoms are the first prominent symptoms
2. MSA-P when parkinson symptoms are the first prominent symptoms

The term MSA-A was once used to denote autonomic difficulties, however the most recent consensus guidelines on the diagnosis of Multiple System Atrophy specify that autonomic and/or urinary dysfunction is included in both MSA-C and MSA-P. Multiple System Atrophy is not known to be hereditary, but occurs sporadically with no known family history. It affects both males and females primarily in middle age. Statistical data gives the average age of onset at 50 and the average course of the disease at about 10 years. With knowledge and vigilant medical care, the most troubling symptoms can be managed however and life expectancy can be extended.

For MSA Caregivers
06/09/2025

For MSA Caregivers

REGISTER NOW - FOUR DAYS LEFT (IN-PERSON)

PSP-MSA-CBD Caregiving Symposium, Saturday, June 14, 2025
10am-3pm PT

Register today to ensure your spot! The registration deadline for in-person attendance is Thursday, June 12, at noon PT.

This hybrid event is co-hosted by Brain Support Network and Stanford's Movement Disorders Center. Join us online or in-person at Stanford (lunch provided). In-person attendance at Stanford is limited to 100 people.

Register Today!
In-person: bit.ly/june14atypical-campus
Online : bit.ly/june14atypical-virtual

Speakers include Dale G. Larson, PhD, Clinical Psychologist, Santa Clara University; Jessica Ng, MD, Movement Disorder Specialist, Stanford; Amy Romarate, LCSW, Neurology Social Worker, Stanford; and Christina Irving, LCSW, Director of Client Services, Family Caregiver Alliance.

We will feature a panel of PSP, MSA, CBD Caregivers moderated by Candy Welch, Leader, Brain Support Network's MSA Caregiver Group and Board Member.

Advance registration required

Help us spread the word by sharing this flyer with your healthcare team, your family, and friends: brainsupportnetwork.org/wp-content/uploads/June14RegisterFlyer.pdf

09/02/2022

This MSA research held at the Rocky Mountain Movement Disorders Center is looking to recruit around 60 MSA patients for their study of monoclonal antibodies, hoping to slow down the progression of the disease.

They reimburse some travel expenses and are based in Colorado. See link for more information.
https://cenexelresearch.com/rmcr/trials/multiple-system-atrophy/

04/28/2022

Alterity Therapeutics today announced that the United Kingdom Medicines & Healthcare products Regulatory Agency (MHRA) has accepted Alterity's clinical trial authorisation (CTA) request to conduct its Phase 2 clinical trial for ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating....

03/24/2022

You are one click away from the Multiple System Atrophy (MSA) Research Registry page. By completing the MSA Research Registry page you give the Translational Genomics Research Institute (TGen), permission to contact you with more information related to research, and research participation. It is imp...

02/10/2022

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Pa...

12/16/2021

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

11/12/2021

Lu AF82422 represents a novel approach for potential treatment of multiple system atrophy , which currently represents a high and urgent unmet medical need. H. Lundbeck A/S , announces that it has... | November 11, 2021

11/05/2021

Teva Pharmaceuticals inked a deal with MODAG GmbH to license and develop two of MODAG’s compounds in neurodegenerative disease, anle138b and sery433.

11/01/2021

Multiple system atrophy (MSA) is a neurodegenerative disorder primarily characterized by autonomic failure plus parkinsonism or cerebellar ataxia. The diagnosis may be challenging and is usually made at a tertiary care center. The long-term management issues are equally challenging and frequently re...

Address

Fremont, CA
94539

Website

Alerts

Be the first to know and let us send you an email when CURE M.S.A. (Multiple System Atrophy) posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category